Press Releases

Date Title and Summary Additional Formats
Toggle Summary CHF Solutions Protects New Peripheral Vascular Access Catheter with Patent Application
EDEN PRAIRIE, Minn. , Jan. 12, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application for a peripheral vascular access catheter for use with its
View HTML
Toggle Summary CHF Solutions Announces Meta-Analysis Demonstrates Ultrafiltration is Better than Diuretic Therapy for the Management of Volume Overload in ADHF
EDEN PRAIRIE, Minn. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced a meta-analysis published in Heart Failure Review s concludes that ultrafiltration (UF) increases
View HTML
Toggle Summary CHF Solutions Announces Webinar on Pediatric Ultrafiltration Therapy hosted by Ladenburg Thalman & Co.
EDEN PRAIRIE, Minn. , Dec. 04, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that Ladenburg Thalman & Co. will host a conference call and webcast at 1:00p.m.
View HTML
Toggle Summary CHF Solutions, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EDEN PRAIRIE, Minn. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS), today announced that, effective November 16, 2020 , the independent directors approved three equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to three individuals
View HTML
Toggle Summary CHF Solutions, Inc. Announces 52 Percent Increase in Revenue for Third Quarter 2020 and Provides Company Update
EDEN PRAIRIE, Minn. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the third quarter ended September 30, 2020 . Recent Highlights Revenue for the third quarter of 2020 was $1.9 million , an increase of 52% compared to the prior year period
View HTML
Toggle Summary CHF Solutions, Inc. To Announce Third Quarter 2020 Financial Results on November 10, 2020
EDEN PRAIRIE, Minn. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its third quarter 2020 financial results will be released on Tuesday, November 10, 2020 . The company will host a conference call and webcast at 9:00 AM ET that morning, during which
View HTML
Toggle Summary CHF Solutions Announces First Commercial Shipments of Aquadex Systems to Brazil, following Regulatory Approval
EDEN PRAIRIE, Minn. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced it has shipped the first commercial orders of its Aquadex SmartFlow™ system to Brazil , following
View HTML
Toggle Summary CHF Solutions Announces Deployment of Aquadex Systems to Hospitals in the Southeast to Treat COVID-19 Patients
EDEN PRAIRIE, Minn. , Oct. 27, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that it has shipped Aquadex™ product to medical facilities in Tennessee and South Carolina to
View HTML
Toggle Summary CHF Solutions Submits Patent Application to Improve Venous Blood Flow and Ultrafiltration Efficiency
EDEN PRAIRIE, Minn. , Oct. 23, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application for a new technological advance to the Aquadex SmartFlow™
View HTML
Toggle Summary CHF Solutions Announces Data Demonstrating Benefit of Aquadex Therapy for Treatment of Heart Failure and COVID-19
EDEN PRAIRIE, Minn. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced data from a retrospective study and a case study supporting the benefit of Aquadex™ therapy in
View HTML